Showing results (401-410 of 2,609) with videos related to

Sort By:
Pageof 261
Oncology Research|December 14, 2020
Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the LiteratureLinn Woelber, Sabrina Mathey, Katharina Prieske, et al.
Oncology Research|May 4, 2019
FCY-302, a Novel Small Molecule, Induces Apoptosis in Leukemia and Myeloma Cells by Attenuating Key Antioxidant and Mitochondrial EnzymesPrasanna Rajagopalan, Abdulrahim Hakami, Mohammed Ragab, et al.
Oncology Research|May 5, 2019
Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort StudyPing Wen, Sheng-Duo Chen, Jia-Rui Wang, et al.
Oncology Research|April 16, 2019
MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic TrioxideZhiguo Wang, Zehui Fang, Runzhang Lu, et al.
Oncology Research|August 23, 2018
Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese PatientsKai Zhang, Huajun Chen, Ye Wang, et al.
Oncology Research|May 4, 2019
Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast CancerAnnemarie E M Post, Johan Bussink, Fred C G J Sweep, et al.
Oncology Research|August 22, 2018
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone TherapyTakashi Saito, Atsuo Okamura, Junichiro Inoue, et al.
Oncology Research|May 11, 2019
miR-186 Suppresses the Progression of Cholangiocarcinoma Cells Through Inhibition of Twist1Ming Zhang, Baochang Shi, Kai Zhang
Oncology Research|July 5, 2019
The lncRNA FEZF1-AS1 Promotes the Progression of Colorectal Cancer Through Regulating OTX1 and Targeting miR-30a-5pJing Li, Lian-Mei Zhao, Cong Zhang, et al.
Oncology Research|October 16, 2019
Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression LevelsXiuhua Weng, Shaohong Luo, Shen Lin, et al.
Pageof 261